Capricor Therapeutics
CAPR
56 hedge funds and large institutions have $32.7M invested in Capricor Therapeutics in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 5 closing their positions.
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
175% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $377K
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
64% more capital invested
Capital invested by funds: $19.9M → $32.7M (+$12.8M)
51% more funds holding
Funds holding: 37 → 56 (+19)
2.14% more ownership
Funds ownership: 13.21% → 15.35% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$969K |
| 3 |
Goldman Sachs
New York
|
+$957K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$808K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$491K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$4.34M |
| 2 |
Renaissance Technologies
New York
|
-$451K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$161K |
| 4 |
LPL Financial
San Diego,
California
|
-$154K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$84.8K |
CAPR Hedge Fund Activity: Q1 2024 in Review
56 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2024, worth a combined $32.7M — up 64% from $19.9M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CAPR positions and 5 closed out — a net gain of 19 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.32M. The largest seller was Woodline Partners, cutting an estimated $4.34M.
- 56 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2024, up from 37 in Q4 2023.
- Funds reported $32.7M of Capricor Therapeutics stock for Q1 2024, up 64% quarter-over-quarter.
- 24 funds opened new Capricor Therapeutics positions in Q1 2024 and 5 closed out, a net change of +19 holders.
- The largest Capricor Therapeutics buyer in Q1 2024 was Millennium Management, an estimated $1.32M added.
- The largest Capricor Therapeutics seller in Q1 2024 was Woodline Partners, an estimated $4.34M sold.
Based on aggregated 13F filings for Q1 2024.